Trial Profile

A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE COMPARATOR, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833 AND PF-06651600 ALONE AND IN COMBINATION COMPARED TO TOFACITINIB ALONE IN PARTICIPANTS WITH MODERATELY-SEVERELY ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ritlecitinib (Primary) ; Tofacitinib (Primary) ; Zimlovisertib (Primary)
Indications Rheumatoid arthritis
Focus Therapeutic Use
Sponsors Pfizer

02 Mar 2022 Status changed from active, no longer recruiting to completed.
22 Feb 2022 This trial has been completed in Slovakia (end date:2022-02-07), according to European Clinical Trials Database record.
16 Feb 2022 This trial has been completed in Bulgaria(end date:2022-02-07), according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com